Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
3(23%)
Results Posted
20%(1 trials)
Terminated
1(8%)

Phase Distribution

Ph not_applicable
4
31%
Ph phase_2
3
23%
Ph phase_3
1
8%

Phase Distribution

0

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 2Efficacy & side effects
3(37.5%)
Phase 3Large-scale testing
1(12.5%)
N/ANon-phased studies
4(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

62.5%

5 of 8 finished

Non-Completion Rate

37.5%

3 ended early

Currently Active

3

trials recruiting

Total Trials

13

all time

Status Distribution
Active(3)
Completed(5)
Terminated(3)
Other(2)

Detailed Status

Completed5
Active, not recruiting2
unknown2
Withdrawn2
Recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
3
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (37.5%)
Phase 31 (12.5%)
N/A4 (50.0%)

Trials by Status

recruiting18%
terminated18%
active_not_recruiting215%
unknown215%
withdrawn215%
completed538%

Recent Activity

3 active trials
Showing 5 of 13
active_not_recruiting

National Cancer Institute "Cancer Moonshot Biobank"

NCT04314401
recruitingphase_2

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

NCT05998135
active_not_recruitingphase_3

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

NCT06432296
completedphase_2

Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

NCT06266091
unknownnot_applicable

Early Use of TIPS With Polytetrafluoroethylene(PTFE) Covered Stents in Cirrhotic Patients With Refractory Ascites

NCT03172273
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT04314401

National Cancer Institute "Cancer Moonshot Biobank"

Active Not Recruiting
NCT05998135Phase 2

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer

Recruiting
NCT06432296Phase 3

Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody

Active Not Recruiting
NCT06266091Phase 2

Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody

Completed
NCT03172273Not Applicable

Early Use of TIPS With Polytetrafluoroethylene(PTFE) Covered Stents in Cirrhotic Patients With Refractory Ascites

Unknown
NCT05220891

Comparison of Crystalloid and Colloid I.V Fluid Therapy in Prevention of Paracentesis Induced Circulatory Dysfunction (PICD) and Renal Dysfunction in Patients With Decompensated Liver Cirrhosis in Egypt: a Randomized Piolet Study

Unknown
NCT02477657

Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology

Withdrawn
NCT01091233

The Influence of Paracentesis on Intra-abdominal Pressure and Kidney Function in Critically Ill Patients With Liver Cirrhosis and Ascites: an Observational Study

Withdrawn
NCT04032600Not Applicable

Malignant Ascites in Ovarian Cancer: Impact of Total Paracentesis on Hemodynamics

Completed
NCT03163745

Asymptomatic Spontaneous Bacterial Peritonitis in Patients With Decompensated Liver Cirrhosis

Completed
NCT01077063Not Applicable

An Early Safety and Efficacy Study of Ascites Management: Standard Paracentesis or Early Intervention With Pleurx Catheters in Patients With Malignant Ascites

Terminated
NCT01923454Not Applicable

Immediate Anterior Chamber Paracentesis With A 30-Gauge Needle for Acute Primary Angle - Closure

Completed
NCT00836654Phase 2

Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group

Completed

All 13 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
13